The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease: A Case Report

Ken Momosaki, Jun Kido, Shiro Matsumoto, Atsuo Taniguchi, Tomoyuki Akiyama, Takaaki Sawada, Shiro Ozasa, Kimitoshi Nakamura

Research output: Contribution to journalArticle

Abstract

Lesch-Nyhan disease (LND) is an X-linked recessive disorder caused by a deficiency in hypoxanthine-guanine phosphoribosyl transferase. Patients with LND experience involuntary movements, including dystonia, choreoathetosis, opisthotonos, ballismus, and self-injury. Alleviating these involuntary movements is important to improve the quality of life in patients with LND. Many clinicians have difficulty controlling these involuntary movements in their patients, and there are no established and effective treatments. A 6-month-old boy with LND presented with generalized dystonia and self-injury behavior that was alleviated after receiving S-adenosylmethionine (SAMe). His self-injury behavior completely resolved after he received SAMe and risperidone. Although he had often experienced inspiratory stridor because of laryngeal dystonia and frequently developed aspiration pneumonitis and bronchitis, no inspiratory stridor was noted after SAMe treatment. The patient is continuing to receive SAMe and risperidone. SAMe treatment alleviates dystonic movements and improves quality of life in pediatric patients with LND. Additional research is needed to determine the long-term safety and efficacy of SAMe and its appropriate dosage.

Original languageEnglish
Pages (from-to)256-264
Number of pages9
JournalCase Reports in Neurology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Lesch-Nyhan Syndrome
S-Adenosylmethionine
Dyskinesias
Phenotype
Dystonia
Risperidone
Respiratory Sounds
Wounds and Injuries
Therapeutics
Quality of Life
Hypoxanthine
Bronchitis
Guanine
Transferases
Pneumonia
Pediatrics
Safety
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease : A Case Report. / Momosaki, Ken; Kido, Jun; Matsumoto, Shiro; Taniguchi, Atsuo; Akiyama, Tomoyuki; Sawada, Takaaki; Ozasa, Shiro; Nakamura, Kimitoshi.

In: Case Reports in Neurology, 01.01.2019, p. 256-264.

Research output: Contribution to journalArticle

Momosaki, Ken ; Kido, Jun ; Matsumoto, Shiro ; Taniguchi, Atsuo ; Akiyama, Tomoyuki ; Sawada, Takaaki ; Ozasa, Shiro ; Nakamura, Kimitoshi. / The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease : A Case Report. In: Case Reports in Neurology. 2019 ; pp. 256-264.
@article{c83b3afefcda4ca2bfad4bd86e317fce,
title = "The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease: A Case Report",
abstract = "Lesch-Nyhan disease (LND) is an X-linked recessive disorder caused by a deficiency in hypoxanthine-guanine phosphoribosyl transferase. Patients with LND experience involuntary movements, including dystonia, choreoathetosis, opisthotonos, ballismus, and self-injury. Alleviating these involuntary movements is important to improve the quality of life in patients with LND. Many clinicians have difficulty controlling these involuntary movements in their patients, and there are no established and effective treatments. A 6-month-old boy with LND presented with generalized dystonia and self-injury behavior that was alleviated after receiving S-adenosylmethionine (SAMe). His self-injury behavior completely resolved after he received SAMe and risperidone. Although he had often experienced inspiratory stridor because of laryngeal dystonia and frequently developed aspiration pneumonitis and bronchitis, no inspiratory stridor was noted after SAMe treatment. The patient is continuing to receive SAMe and risperidone. SAMe treatment alleviates dystonic movements and improves quality of life in pediatric patients with LND. Additional research is needed to determine the long-term safety and efficacy of SAMe and its appropriate dosage.",
author = "Ken Momosaki and Jun Kido and Shiro Matsumoto and Atsuo Taniguchi and Tomoyuki Akiyama and Takaaki Sawada and Shiro Ozasa and Kimitoshi Nakamura",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000502568",
language = "English",
pages = "256--264",
journal = "Case Reports in Neurology",
issn = "1662-680X",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease

T2 - A Case Report

AU - Momosaki, Ken

AU - Kido, Jun

AU - Matsumoto, Shiro

AU - Taniguchi, Atsuo

AU - Akiyama, Tomoyuki

AU - Sawada, Takaaki

AU - Ozasa, Shiro

AU - Nakamura, Kimitoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lesch-Nyhan disease (LND) is an X-linked recessive disorder caused by a deficiency in hypoxanthine-guanine phosphoribosyl transferase. Patients with LND experience involuntary movements, including dystonia, choreoathetosis, opisthotonos, ballismus, and self-injury. Alleviating these involuntary movements is important to improve the quality of life in patients with LND. Many clinicians have difficulty controlling these involuntary movements in their patients, and there are no established and effective treatments. A 6-month-old boy with LND presented with generalized dystonia and self-injury behavior that was alleviated after receiving S-adenosylmethionine (SAMe). His self-injury behavior completely resolved after he received SAMe and risperidone. Although he had often experienced inspiratory stridor because of laryngeal dystonia and frequently developed aspiration pneumonitis and bronchitis, no inspiratory stridor was noted after SAMe treatment. The patient is continuing to receive SAMe and risperidone. SAMe treatment alleviates dystonic movements and improves quality of life in pediatric patients with LND. Additional research is needed to determine the long-term safety and efficacy of SAMe and its appropriate dosage.

AB - Lesch-Nyhan disease (LND) is an X-linked recessive disorder caused by a deficiency in hypoxanthine-guanine phosphoribosyl transferase. Patients with LND experience involuntary movements, including dystonia, choreoathetosis, opisthotonos, ballismus, and self-injury. Alleviating these involuntary movements is important to improve the quality of life in patients with LND. Many clinicians have difficulty controlling these involuntary movements in their patients, and there are no established and effective treatments. A 6-month-old boy with LND presented with generalized dystonia and self-injury behavior that was alleviated after receiving S-adenosylmethionine (SAMe). His self-injury behavior completely resolved after he received SAMe and risperidone. Although he had often experienced inspiratory stridor because of laryngeal dystonia and frequently developed aspiration pneumonitis and bronchitis, no inspiratory stridor was noted after SAMe treatment. The patient is continuing to receive SAMe and risperidone. SAMe treatment alleviates dystonic movements and improves quality of life in pediatric patients with LND. Additional research is needed to determine the long-term safety and efficacy of SAMe and its appropriate dosage.

UR - http://www.scopus.com/inward/record.url?scp=85072545112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072545112&partnerID=8YFLogxK

U2 - 10.1159/000502568

DO - 10.1159/000502568

M3 - Article

AN - SCOPUS:85072545112

SP - 256

EP - 264

JO - Case Reports in Neurology

JF - Case Reports in Neurology

SN - 1662-680X

ER -